Can biotech bounce back?

Can biotech bounce back?

Biotechnology stocks have been suffering a decline for some months. But while the sector faces some challenges, attractive valuations and a rapid pace of medical innovation could become difficult for investors to ignore, says Portfolio Manager Andy Acker.

The haves and have-nots of US high yield

The haves and have-nots of US high yield

In this video, Rebecca Young, Portfolio Manager within the Strategic Fixed Income team, explains why there is more than meets the eye in the US high yield market and discusses the teams approach to achieving ‘sensible income’.

Growth slowing but precipitous drop unlikely
Quick Views Volatility

Growth slowing but precipitous drop unlikely

A new video, ‘Growth slowing but precipitous drop unlikely’, is now available on the blog.

Although the current economic expansion is ageing (bringing us nearer to a recession) leading indicators do not indicate a sharp contraction. What does that mean for equity investors? Director of Research Carmel Wellso explains.



Balanced Fund

For 25 years, this dynamic allocation strategy has delivered our equity and fixed income expertise in a one-stop core solution.


Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or improving efficiencies.


Global Technology Fund

Our deep and experienced tech team seeks growth through innovation in this complex and dynamic sector.